$NEXI
NexImmune, Inc. Stock $nexi

$nexi Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000153821023000019 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.900M	$3.701M
YoY Change	-30.79%	-21.03%
% of Gross Profit
Research & Development	$4.880M	$6.124M
YoY Change	-58.77%	-41.39%
% of Gross Profit
Depreciation & Amortization	$267.1K	$263.8K
YoY Change	10.0%	16.22%
% of Gross Profit
Operating Expenses	$7.785M	$9.825M
YoY Change	-51.12%	-34.73%
Operating Profit	-$7.785M	-$9.825M
YoY Change	-51.12%	-34.73%
Interest Expense	$220.0K	$274.7K
YoY Change
% of Operating Profit
Other Income/Expense, Net	$218.2K	$260.3K
YoY Change	234.72%	753.07%
Pretax Income	-$7.570M	-$9.565M
YoY Change	-52.27%	-36.33%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$7.567M	-$9.565M
YoY Change	-52.29%	-36.33%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.29	-$0.37
Diluted Earnings Per Share	-$0.29	-$0.37
COMMON SHARES
Basic Shares Outstanding	26.08M shares	26.08M shares
Diluted Shares Outstanding	26.08M shares	26.08M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.28M	$22.32M
YoY Change	-69.36%	-65.67%
Cash & Equivalents	$16.28M	$22.32M
Short-Term Investments
Other Short-Term Assets	$304.9K	$269.5K
YoY Change	333.16%	112.19%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$18.50M	$25.40M
YoY Change	-68.95%	-64.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.971M	$4.233M
YoY Change	-15.68%	-5.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$300.2K	$190.6K
YoY Change	105.6%	-67.89%
Total Long-Term Assets	$4.974M	$5.260M
YoY Change	-18.15%	-18.0%
TOTAL ASSETS
Total Short-Term Assets	$18.50M	$25.40M
Total Long-Term Assets	$4.974M	$5.260M
Total Assets	$23.47M	$30.66M
YoY Change	-64.25%	-60.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$582.5K	$650.6K
YoY Change	-64.75%	-67.6%
Accrued Expenses	$5.140M	$5.548M
YoY Change	-25.2%	23.35%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.268M	$6.786M
YoY Change	-31.23%	-4.3%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$203.9K	$300.2K
YoY Change	-70.85%	-63.8%
Total Long-Term Liabilities	$203.9K	$300.2K
YoY Change	-70.85%	-63.8%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.268M	$6.786M
Total Long-Term Liabilities	$203.9K	$300.2K
Total Liabilities	$6.471M	$7.086M
YoY Change	-34.05%	-10.53%
SHAREHOLDERS EQUITY
Retained Earnings	-$207.4M	-$199.8M
YoY Change	30.77%	39.92%
Common Stock	$2.608K	$2.608K
YoY Change	13.94%	14.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$17.00M	$23.58M
YoY Change
Total Liabilities & Shareholders Equity	$23.47M	$30.66M
YoY Change	-64.25%	-60.84%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$7.567M	-$9.565M
YoY Change	-52.29%	-36.33%
Depreciation, Depletion And Amortization	$267.1K	$263.8K
YoY Change	10.0%	16.22%
Cash From Operating Activities	-$6.029M	-$12.28M
YoY Change	-48.57%	-25.44%
INVESTING ACTIVITIES
Capital Expenditures	$5.020K	$42.72K
YoY Change	-104.05%	-87.59%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	-$5.020K	-$42.72K
YoY Change	-100.02%	-100.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$0.00
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities	-6.029M	-$12.28M
Cash From Investing Activities	-5.020K	-$42.72K
Cash From Financing Activities	0.000	$0.00
Net Change In Cash	-6.034M	-$12.33M
YoY Change	-137.3%	111.7%
FREE CASH FLOW
Cash From Operating Activities	-$6.029M	-$12.28M
Capital Expenditures	$5.020K	$42.72K
Free Cash Flow	-$6.034M	-$12.33M
YoY Change	-47.98%	-26.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001538210
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-40045
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	NEXIMMUNE, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	42-2518457
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	9119 Gaither Road
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Gaithersburg,
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20877
CY2023Q1	dei	City Area Code CityAreaCode	301
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	825-9810
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2023Q1	dei	Trading Symbol TradingSymbol	NEXI
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	26078451	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22315215	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34642340	usd
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	55000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	55000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3034485	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2671411	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	25404700	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	37368751	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4232655	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4459071	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	836292	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	967032	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	190583	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	264970	usd
CY2023Q1	us-gaap	Assets Assets	30664230	usd
CY2022Q4	us-gaap	Assets Assets	43059824	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	650568	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2377374	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5547648	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7357153	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	587944	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	599047	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6786160	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10333574	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	300217	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	425766	usd
CY2023Q1	us-gaap	Liabilities Liabilities	7086377	usd
CY2022Q4	us-gaap	Liabilities Liabilities	10759340	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26078451	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26078451	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26078451	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26078451	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	2608	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2608	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	223389976	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	222547530	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-199814731	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-190249654	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	23577853	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	30517	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	32300484	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30664230	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	43059824	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6124044	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10448843	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3701365	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4604679	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	9825409	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	15053522	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9825409	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15053522	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	274738	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	33093	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-14406	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2576	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	260332	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	32300484	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9565077	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-15023005	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.66
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26078451	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26078451	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22836781	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22836781	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9565077	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-15023005	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-23590	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9565077	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15046595	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	842446	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9565077	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	23577853	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	83760667	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	33255	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1645852	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-23590	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-15023005	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	70393179	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9565077	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-15023005	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	263766	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	226956	usd
CY2023Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	usd
CY2022Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	1618	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	842446	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1645852	usd
CY2023Q1	nexi	Lease Expense Noncash LeaseExpenseNoncash	130740	usd
CY2022Q1	nexi	Lease Expense Noncash LeaseExpenseNoncash	121904	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	288687	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2696917	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1726806	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	955433	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1804135	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1596261	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-136652	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-107810	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12284405	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16475466	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	42720	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	344362	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	16036445	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0	usd
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	27000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-42720	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10619193	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	33255	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	33255	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12327125	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5823018	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34697340	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30393852	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22370215	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24570834	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	62241	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-199800000	usd
CY2023Q1	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	0	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22300000	usd
CY2023Q1	us-gaap	Cash Cash	1354694	usd
CY2022Q4	us-gaap	Cash Cash	2940733	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22315215	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34642340	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	22370215	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	34697340	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	269542	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	401916	usd
CY2023Q1	nexi	Prepaid Research And Development Expenses PrepaidResearchAndDevelopmentExpenses	856399	usd
CY2022Q4	nexi	Prepaid Research And Development Expenses PrepaidResearchAndDevelopmentExpenses	1176491	usd
CY2023Q1	nexi	Prepaid Maintenance Agreements PrepaidMaintenanceAgreements	361034	usd
CY2022Q4	nexi	Prepaid Maintenance Agreements PrepaidMaintenanceAgreements	369606	usd
CY2023Q1	us-gaap	Prepaid Insurance PrepaidInsurance	1108624	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	403653	usd
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	355067	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	245278	usd
CY2023Q1	us-gaap	Interest Receivable InterestReceivable	83819	usd
CY2022Q4	us-gaap	Interest Receivable InterestReceivable	74467	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3034485	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2671411	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7726013	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7688663	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3493358	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3229592	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4232655	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4459071	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	300000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	200000	usd
CY2023Q1	nexi	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	2892787	usd
CY2022Q4	nexi	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	3210794	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2232188	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3855797	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	393806	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	267383	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	28867	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	23179	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5547648	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7357153	usd
CY2023Q1	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	75000	usd
CY2021Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	50000	usd
CY2022Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2023Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2022Q4	nexi	Restructuring And Related Cost Expected Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent	0.30
CY2022Q4	nexi	Restructuring And Related Cost Number Of Positions Before Eliminations RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations	74	employee
CY2022Q4	nexi	Restructuring And Related Cost Number Of Positions After Eliminations RestructuringAndRelatedCostNumberOfPositionsAfterEliminations	50	employee
CY2022Q4	us-gaap	Restructuring And Related Cost Expected Cost1 RestructuringAndRelatedCostExpectedCost1	700000	usd
CY2022	us-gaap	Restructuring Charges RestructuringCharges	500000	usd
CY2022Q4	us-gaap	Restructuring Reserve RestructuringReserve	382389	usd
CY2023Q1	us-gaap	Restructuring Charges RestructuringCharges	126170	usd
CY2023Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	452112	usd
CY2023Q1	us-gaap	Restructuring Reserve RestructuringReserve	56447	usd
CY2018Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1741770	shares
CY2021Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	5202624	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1863566	shares
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	842446	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1645852	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3965502	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.38
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023Q1	nexi	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod	841	shares
CY2023Q1	nexi	Share Based Compensation Arrangements By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice	10.50
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	194933	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.95
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3769728	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.45
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M18D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3769728	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.45
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y3M18D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2082403	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	9.09
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y3M18D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1687325	shares
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	5.42
CY2023Q1	nexi	Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Outstanding Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1	P8Y10M24D
CY2023Q1	nexi	Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.99
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.788
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.790
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.015
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.017
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	5200000	usd
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2942868	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9565077	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-15023005	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.66
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26078451	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26078451	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22836781	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22836781	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5305328	shares
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q1	us-gaap	Share Price SharePrice	0.41

Files In Submission

Name	View Source	Status
nexi-20230331_cal.xml	Edgar Link	unprocessable
0001538210-23-000019-index-headers.html	Edgar Link	pending
0001538210-23-000019-index.html	Edgar Link	pending
0001538210-23-000019.txt	Edgar Link	pending
0001538210-23-000019-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nexi-20230331.htm	Edgar Link	pending
nexi-20230331.xsd	Edgar Link	pending
nexi-20230331xexx311.htm	Edgar Link	pending
nexi-20230331xexx312.htm	Edgar Link	pending
nexi-20230331xexx321.htm	Edgar Link	pending
nexi-20230331xexx322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
nexi-20230331_def.xml	Edgar Link	unprocessable
nexi-20230331_lab.xml	Edgar Link	unprocessable
nexi-20230331_pre.xml	Edgar Link	unprocessable
nexi-20230331_htm.xml	Edgar Link	completed
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NEXI
NexImmune, Inc. Stock $nexi

2023 Q2 Form 10-Q Financial Statement

#000153821023000019 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NEXI NexImmune, Inc. Stock $nexi

2023 Q2 Form 10-Q Financial Statement

#000153821023000019 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NEXI
NexImmune, Inc. Stock $nexi